scholarly journals Survival of borderline resectable pancreatic cancer patients receiving neoadjuvant therapy and surgery

HPB ◽  
2017 ◽  
Vol 19 ◽  
pp. S96-S97
Author(s):  
M. Aldakkak ◽  
S. Tsai ◽  
B. George ◽  
P.S. Ritch ◽  
K. Dua ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer

Management of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

2019 ◽  
Author(s):  
Francis Igor Macedo ◽  
Danny Yakoub ◽  
Vikas Dudeja ◽  
Nipun B. Merchant
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
The United States ◽  
Locally Advanced Pancreatic Cancer ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer ◽  
Number Of Patients

The incidence of pancreatic cancer continues to rise, and it is now the third-leading cause of cancer-related deaths in the United States. Only 15 to 20% of patients are eligible to undergo potentially curative resection, as most tumors are deemed unresectable at the time of diagnosis because of either locally advanced disease or distant metastases. Improvements in preoperative CT imaging have enabled better determination of the extent of disease and allowed for better operative planning. Based on their relationship to the surrounding vasculature and structures and presence or absence of distant disease, pancreatic tumors are classified into four categories: resectable, borderline resectable pancreatic cancer (BRPC), locally advanced pancreatic cancer (LAPC), and metastatic. With the recent advent of more effective chemotherapy regimens, efforts have focused on using neoadjuvant therapy approaches to increase the likelihood of achieving an R0 in patients with BRPC and possibly convert unresectable, locally advanced tumors to potentially resectable tumors. Response with neoadjuvant therapy regimens has resulted in increased number of patients eligible for resection, many times requiring vascular resection. Herein, we describe recent changes in the classification, important surgical and pathologic considerations and updated multimodal therapeutic options in the complex management of BRPC and LAPC.  This review contains 5 figures, 2 tables, and 78 references. Key Words: borderline resectable pancreatic cancer, CA 19-9, FOLFIRINOX, locally advanced pancreatic cancer, nab-paclitaxel, neoadjuvant chemotherapy, pancreatectomy, portal vein resection, radiation therapy, gemcitabine

Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer

2019 ◽  
Vol 18 (4) ◽  
pp. 373-378 ◽  
Author(s):  
June S Peng ◽  
Jane Wey ◽  
Sricharan Chalikonda ◽  
Daniela S Allende ◽  
R Matthew Walsh ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Tumor Response ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer

Mo1660 Neoadjuvant Therapy Followed by Surgical Resection for Borderline Resectable Pancreatic Cancer With Artery Involvement

2015 ◽  
Vol 148 (4) ◽  
pp. S-1164
Author(s):  
Hiroki Yamaue ◽  
Seiko Hirono ◽  
Manabu Kawai ◽  
Ken-ichi Okada ◽  
Motoki Miyazawa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Surgical Resection ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer

Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer

Surgery ◽  
2020 ◽  
Vol 168 (3) ◽  
pp. 440-447 ◽  
Author(s):  
Chad A. Barnes ◽  
Mohammed Aldakkak ◽  
Kathleen K. Christians ◽  
Callisia N. Clarke ◽  
Kulwinder Dua ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Disease Recurrence ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer
Sign in / Sign up

Export Citation Format

Share Document